Omeros (OMER) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Omeros (OMER) Names New Chief Business, Commercial Officer
May 10, 2016 7:08 AM EDTOmeros Corporation (NASDAQ: OMER) announced the hiring of Leonard Blum as chief business and commercial officer. Mr. Blum is leading the companys sales, marketing, commercial strategy and planning, and business development, including for OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% and the companys growing pipeline of development-stage programs.
Mr. Blum brings over 28 years of executive and management experience in the pharmaceutical industry. Most recently Mr. Blum served as senior vice president, chief commercial officer from 2007 until March 2016 at Theravance, Inc. and its spin-off Theravance... More
Omeros (OMER) Enters Supply, Distribution Agreement for OMIDRIA in the Middle East
May 10, 2016 7:08 AM EDTOmeros Corporation (Nasdaq: OMER) announced entry into an exclusive supply and distribution agreement for the sale of OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% in the Kingdom of Saudi Arabia, the United Arab Emirates and other countries in the Middle East with ITROM Trading Drug Store (ITROM). ITROM is Dubai-based and an internationally recognized pharmaceutical marketing and distribution company specializing in ophthalmology. Under the agreement, ITROM will be responsible for obtaining marketing authorizations for OMIDRIA within the licensed territory and for marketing, selling and distributing product supplied by Omeros. Existing ophthalmology medical sales representatives... More
